The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Morning All, Lindy speaking and presenting todat at NeoAg Summit 2019 Boston. What does the industry see that the market doesn"t??
Lindy Durrant
Lindy Durrant
Company: Scancell Ltd
Job title: CSO
Bio:
Lindy is Professor of Cancer Immunotherapy at the University of Nottingham and CSO of Scancell Ltd. She has developed two vaccine platforms ImmunoBodyTM and ModitopeTM which induce potent killer CD8 T cells and and cytotoxic CD4 T cells to post-translational modifications respectively. The first ImmunoBodyTM, SCIB1, has completed a phase I/II clinical trial in which 14/16 patients with melanoma have been disease free for five years. The first product from the ModitopeTM platform will enter the clinic next year. Lindy has over 150 peer reviewed publications and is also the inventor on 66 patents, 55 of which have been awarded. She was award of the Waldenstrom prize for cancer Immunotherapy in 2018.
In fairness I think we all know what the maket needs to see.
Just a 50k sell at 5.115 today, MMs taking up to 220k (still) at 5.11. Off to UCLH for a change today, lol, have a good weekend all.
I would love to hear Lindy's presentation at this conference to a group of fellow scientists.
Likewise the lecture she gave when presented with the Waldenstrom prize.
Funny enough Ray I emailed CH last night with a couple of questions and asked if there was anyway we could get a recording of Lindys presentation. Will let you know
Thanks C7.
C7, just seen the question you posed earlier...
"What does the industry see that the market doesn"t??"
Probably plenty, and vice versa. They are looking at/for different things. The scientific community are interested in the science, the research and techniques regardless of the financial potential. The markets are simply looking at how much of a return is this likely to make in the next n months/years.
We know the two have a tenuous link but I'm not sure all factions see it like that. In fact, I am sure - look at the share price!
"What does the industry see that the market doesn"t??"
everything under NDA
all the latest developments on TCR
all the developments of SCIB2
all the developments on MABS
and hidden from all ...
all future patent applications
Ruckrover ... Look at share price
I know you have your valuations ... which i find "simple" ....
here is one from Scancell
SCIB1 In combination with checkpoint inhibitors in patients with late stage disease to increase efficacy without
compromising safety
? As monotherapy in patients with resected disease (adjuvant setting) to delay or prevent recurrence
? 260,000 patients with stage IIB, IIC, and III melanoma, of which 45% can be treated with SCIB1* at an
estimated annual treatment cost of $40k representing a $4b market in the US alone
The reason why i keep saying SCIB1 ... easily covers the Shareprice ... is because it does .........
the rest is a bonus ...
Tf please chill .. it will happen
You are right Inan.
I should have added the word "personalised".
What Lindy specifically wasn't keen on was the approach of Genentech/BionTech
https://www.gene.com/stories/advances-in-the-cancer-immunity-cycle?topic=epigenetics
I see Isa Pharmaceuticals and Polypeptide are represented
https://neo-antigen.com/speaker/willem-jan-krebber/
https://neo-antigen.com/speaker/trishul-shah/
Inan,
"The reason why i keep saying SCIB1 ... easily covers the Shareprice ... is because it does ......…"
Is that the best argument you've got lol!
FWIW, I think SCIB1 COULD easily cover the share price but it all depends on it getting to market. That seems a long way off at the moment. If it did get to market by say 2026, it could be worth 25p/share (SCIB1 alone based on a £4B market)
Sorry, that should be $4B not £4B.
Hi Ruck................."".In fairness I think we all know what the maket needs to see.""
Yep, you hit it on the nail
If it did get to market by say 2026, it could be worth 25p/share (SCIB1 alone based on a £4B market)
LOL ........... US = $4b
so worth 25p a share . ?
are you for real ?
Just to add.....
25p in 2027 equates to an NPV of 6p (using a 20% discount rate) .
So yes, today's share price is covered by SCIB1 alone.
So buy today at 5p and get a 20% per annum return by 2027.
what ever ....
"abbot Maths"
$4 billion of sales US alone = 25p a share ?
Inan,
These are the assumptions I have used:
Market Value $4B
Market share 6.9 percent
Royalty to SCLP 17.5 percent
Net Profit 20 percent
Exchange rate 1 GBP = 1.30 USD
PE Ration 20
Assumes another £6M to be raised at 5p
"abbot Maths"
Inan,
Don't ridicule it just because you don't understand it.
The "maths" is a pretty standard financial calculation.
More than happy to debate the input parameters if you like but the formula is sound I can assure you.
We could of course use your formula....
Market size = BIG BUCKS
Market share = 100 percent (because Scancell are great)
SP = £8
Royalty is 100% to the bottom line .... less the cost of banking the cheque
what is this 20% profit nonsense ?
No company makes 100% net profit!
What about buildings, salaries, manufacturing costs, further research, IT equipment, travel etc etc etc.
who is the competition ... Keytruda ...lol
so why 6.9 percent ... Market share
Maybe if you were CEO you could persuade everyone to work for nothing, get premises rent free, free flights etc?
There are a lot of players in the Melanoma space. Trinity Delta were predicting 2.3% market share (of $14.1B)